Next Article in Journal
Phase II Trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with Prior Anthracycline Exposure for Metastatic Breast Cancer
Previous Article in Journal
What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 2
10.3747/co.19.862
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Translation

EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer

by
S. Kamel–Reid
1,
G. Chong
2,
D.N. Ionescu
3,
A.M. Magliocco
4,
A. Spatz
2,
M. Tsao
1,
X. Weng
5,
S. Young
6,
T. Zhang
1 and
D. Soulieres
5,*
1
Department of Pathology, The University Health Network, Toronto, ON
2
Department of Pathology, McGill University, Jewish General Hospital, Montreal, QC, Canada
3
BC Cancer Agency, Vancouver, BC, Canada
4
Departments of Oncology, Pathology, and Laboratory Medicine, University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada
5
Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(2), 67-74; https://doi.org/10.3747/co.19.862
Submission received: 6 January 2012 / Revised: 4 February 2012 / Accepted: 2 March 2012 / Published: 1 April 2012

Abstract

Background: Non-small-cell lung cancer (NSCLC) tumours with activating mutations of the epidermal growth factor receptor (EFGR) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of NSCLC based on EFGR mutation status. However, no standardized method exists for assessing the EGFR mutation status of tumours. Also, it is not known if available methods are feasible for routine screening. To address that question, we conducted a validation study of methods used for detecting EGFR mutations in exons 19 and 21 at molecular laboratories located in five specialized Canadian cancer centres. Methods: The screening methods were first optimized using cell lines harbouring the mutations in question. A validation phase using anonymized patient samples followed. Results: The methods used at the sites were highly specific and sensitive in detecting both mutations in cell-line DNA (specificity of 100% and sensitivity of at least 1% across all centres). In the validation phase, we observed excellent concordance between the laboratories for detecting mutations in the patient samples. Concordant results were obtained in 26 of 30 samples (approximately 87%). In general, the samples for which results were discordant were also less optimal, containing small amounts of tumour. Conclusions: Our results suggest that currently available methods are capable of reliably detecting exon 19 and exon 21 mutations of EFGR in tumour samples (provided that sufficient tumour material is available) and that routine screening for those mutations is feasible in clinical practice.
Keywords: non-small-cell lung cancer; epidermal growth factor receptor; genetic testing; gefitinib; erlotinib non-small-cell lung cancer; epidermal growth factor receptor; genetic testing; gefitinib; erlotinib

Share and Cite

MDPI and ACS Style

Kamel–Reid, S.; Chong, G.; Ionescu, D.N.; Magliocco, A.M.; Spatz, A.; Tsao, M.; Weng, X.; Young, S.; Zhang, T.; Soulieres, D. EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. Curr. Oncol. 2012, 19, 67-74. https://doi.org/10.3747/co.19.862

AMA Style

Kamel–Reid S, Chong G, Ionescu DN, Magliocco AM, Spatz A, Tsao M, Weng X, Young S, Zhang T, Soulieres D. EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. Current Oncology. 2012; 19(2):67-74. https://doi.org/10.3747/co.19.862

Chicago/Turabian Style

Kamel–Reid, S., G. Chong, D.N. Ionescu, A.M. Magliocco, A. Spatz, M. Tsao, X. Weng, S. Young, T. Zhang, and D. Soulieres. 2012. "EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer" Current Oncology 19, no. 2: 67-74. https://doi.org/10.3747/co.19.862

APA Style

Kamel–Reid, S., Chong, G., Ionescu, D. N., Magliocco, A. M., Spatz, A., Tsao, M., Weng, X., Young, S., Zhang, T., & Soulieres, D. (2012). EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. Current Oncology, 19(2), 67-74. https://doi.org/10.3747/co.19.862

Article Metrics

Back to TopTop